IL6R and colorectal cancer: Blocking the interaction of IL-6 and IL-6R in colitis-associated colorectal cancer (CAC) by anti-IL-6 receptor antibodies reduced the size and number of tumors in mice, and the effect was mediated by the downregulation of HIF-1α [47].